Swedish Life Sciences Stock News

OM:VSURE
OM:VSURECommercial Services

Assessing Verisure (OM:VSURE) Valuation After Q4 2025 Sales Growth And Wider Net Losses

Balancing higher sales and wider losses Verisure (OM:VSURE) has drawn fresh attention after reporting Q4 and full year 2025 results, with sales of €964.7 million in the quarter and €3.7b for the year alongside wider net losses. That mix of higher revenue and larger losses gives you a lot to weigh up, especially given the stock’s recent negative returns over the month and past 3 months. Here is how those headline figures fit together. See our latest analysis for Verisure. Verisure’s latest...
OM:KARNEL B
OM:KARNEL BIndustrials

Karnell Group (OM:KARNEL B) Net Margin Expansion Tests Cautious Earnings Narratives

Karnell Group (OM:KARNEL B) has put up a busy FY 2025 so far, with Q3 revenue of SEK436 million and EPS of SEK0.88 setting the tone against a backdrop of trailing 12 month EPS of SEK2.52 and revenue of SEK1.63 billion, alongside reported earnings growth of 129.6% year on year. The company has seen quarterly revenue move from SEK356.6 million in Q3 2024 to SEK402.9 million in Q4 2024 and then SEK436 million in Q3 2025, while EPS has shifted from SEK0.55 to SEK0.57 and then SEK0.88 over the...
OM:YUBICO
OM:YUBICOSoftware

Yubico (OM:YUBICO) Net Margin Compression Challenges Bullish Growth Narratives

Yubico (OM:YUBICO) FY 2025 earnings snapshot Yubico (OM:YUBICO) has wrapped up FY 2025 with Q4 revenue of 548.3 million SEK and basic EPS of 0.04 SEK, setting the tone for a year where trailing 12 month revenue came in at 2.2 billion SEK and basic EPS was 1.49 SEK. The company has seen quarterly revenue move between 499.1 million SEK and 623.1 million SEK over the past year, with basic EPS ranging from 0.04 SEK to 0.74 SEK. Trailing 12 month EPS and net income have tracked alongside 12 month...
OM:VSURE
OM:VSURECommercial Services

Verisure (OM:VSURE) Q4 Loss Worsens To €121.3m Challenging Bullish Profitability Narratives

Verisure (OM:VSURE) FY 2025 Earnings Snapshot Verisure (OM:VSURE) has wrapped up FY 2025 with fourth quarter revenue of €964.7 million and a basic EPS loss of €0.12, while trailing 12 month figures show revenue of about €3.7 billion and a basic EPS loss of €0.30. Over the past year, the company has seen revenue move from €870.2 million in Q4 2024 to €964.7 million in Q4 2025, while quarterly EPS stayed in loss making territory, shifting from a €0.07 loss per share in Q4 2024 to a €0.12 loss...
OM:CAMX
OM:CAMXPharmaceuticals

Why Camurus (OM:CAMX) Is Down 24.8% After Lifting 2026 Guidance and Showcasing Oxyesa Progress

Camurus AB reported its fourth-quarter and full-year 2025 results, with full-year sales rising to SEK 2,265.38 million and net income to SEK 735.57 million, while issuing 2026 guidance for revenues of SEK 2.60–2.90 billion and operating result of SEK 0.90–1.20 billion. Alongside these results, Camurus highlighted 2025 milestones including EU and UK approvals for Oxyesa in acromegaly and progress in long-acting metabolic therapies, underlining how its product pipeline and regulatory traction...
OM:ZZ B
OM:ZZ BRetail Distributors

3 European Dividend Stocks Offering Up To 5.5% Yield

As the European market continues to show resilience amidst global volatility, with the pan-European STOXX Europe 600 Index reaching new highs and major indexes like Germany's DAX and France's CAC 40 posting gains, investors are increasingly optimistic about the eurozone economy. In this environment of cautious optimism, dividend stocks can offer a compelling opportunity for income-focused investors seeking stability and potential returns; these stocks typically provide regular payouts that...